How mRNA Could Defeat Latent Viruses and Train Immunity Against Cancer

from Biotech Blueprint · host Katerina Roznik

Subscribe to Biotech Blueprint for free at ⁠biotechblueprint.com⁠. About this episode: mRNA’s next chapter isn’t just flu and COVID. We break down why latent viruses (CMV, EBV, HSV) persist, why T cells matter, and how multi-antigen mRNA vaccines aim to control reactivation. We also cover Moderna’s CMV Phase 3 (mRNA-1647) as a platform stress test and the rise of personalized neoantigen cancer vaccines (V940) that cut melanoma recurrence vs Keytruda alone in Phase 2b and are now in Phase 3. What success here would mean for public health, operations, and the mRNA platform.

Episode metadata supplied by the publisher feed · Published Oct 21, 2025

Embed this episode

Attribution link and audio player

Ready to play

How mRNA Could Defeat Latent Viruses and Train Immunity Against Cancer

0:00 51:03

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

Research in Action Oracle Corporation "Research in Action" explores the dynamic world of life sciences, covering drug discovery, clinical trials, therapeutic development, and the pivotal role of real-world data and technology in connecting clinical research with patient care. Hear insightful conversations with scientists, clinicians, and leaders from pharma, biotech, and health.

Frequently Asked Questions

How long is this episode of Biotech Blueprint?

This episode is 51 minutes long.

When was this Biotech Blueprint episode published?

This episode was published on October 21, 2025.

Can I download this Biotech Blueprint episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!